Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Interest Expense

Cost of servicing the company's debt during the period.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $2.78M fell 6.9% year over year, in line with the -7.1% change in trailing-twelve-month interest expense. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.

Context

  • Interest expense amounted to 22.8% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -6.9% holds above the trailing-twelve-month pace of -7.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.78M-1.9% QoQ
Last fiscal yearDec 2025
$11.84M-12.8% YoY
LTMMar 2026
$11.63M-7.1% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.9%——
1 year-12.8%——
3-year CAGR+19.0%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
11.84M USD
Year-over-year change
-12.8%
4-year CAGR
+15.4%

Interest Expense vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.1% is the 5th highest of 7, against a peer median of -6.0%.
  • Interest expense amounts to 22.3% of revenue for OCUL, versus a peer median of 8.0%.
OCUL Competitors
Interest Expense for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$396M USD-7.0%+43.5%7.4%
HROWHarrow Health, Inc.LTM Mar 2026$23.13M USD-3.3%+49.4%8.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026$11.63M USD-7.1%+19.0%22.3%
OCGNOcugen, Inc.LTM Mar 2026$5.02M USD+449.6%—112.5%
GKOSGlaukos CorporationLTM Jun 2026$4.91M USD-11.6%-30.4%0.8%
OCSOculis Holding AGLTM Mar 2026CHF 801.45K CHF-5.0%-50.2%159.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$313.51K USD—-42.5%94.1%
KODKodiak Sciences Inc.LTM Sep 2026$0 USD———
STAASTAAR Surgical CompanyLTM Apr 2026$0 USD——0.0%
SGPSpyGlass Pharma, Inc. Common StockFY2025$0 USD———
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding OCUL) —-6.0%-30.4%8.0%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.